Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 2729 |
| PDBID: | 6PWU |
| Chains: | HL_A |
| Organism: | Human immunodeficiency virus 1, Homo sapiens |
| Method: | EM |
| Resolution (Å): | 6.20 |
| Reference: | 10.1016/j.jmb.2019.11.028 |
| Antibody | |
| Antibody: | PG16 Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | HIV-1 gp160 |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Heavy Chain: H
Mutation: NULL
| >6PWU_H|Chain D[auth H]|Antibody PG16 Fab heavy chain|Homo sapiens (9606) MEFGLSWVFLVALLRGVQCQEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKASGGGSAWSHPQFEKGGGSGGGSGGSSAWSHPQFEK |
Light Chain: L
Mutation: NULL
| >6PWU_L|Chain E[auth L]|Antibody PG16 Fab light chain|Homo sapiens (9606) MAWALLLLTLLTQGTGSWAQSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECSGGSGGHHHHHHHHHH |
Antigen
Chain: A
Mutation: NULL
| >6PWU_A|Chain A, B[auth C], C[auth E]|Envelope glycoprotein gp160|Human immunodeficiency virus 1 (11676) MRVRGIQRNCQHLWRWGTLILGMLMICSAAENLWVTVYYGVPVWKDAETTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIYMENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVQLTPLCVTLDCSYNITNNITNSITNSSVNMREEIKNCSFNMTTELRDKNRKVYSLFYKLDVVQINNGNNSSNLYRLINCNTSALTQACPKVTFEPIPIRYCAPAGYAILKCNDKEFNGTGLCKNVSTVQCTHGIRPVVSTQLLLNGSLAEGKVMIRSENITNNVKNIIVQLNETVTINCTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHCNVSGSQWNRALHQVVGQLREYWNTTIIFKNSSGGDLEITTHSFNCGGEFFYCNTSGLFNSNWTHNDTASMKPNDTITLPCRIKQIINMWQRVGQAIYAPPIQGVIRCESNITGLILTRDGGGNINESQIFRPGGGDMRDNWRSELYKYKVVRIEPLGVAPTKAKRRVVEREKRAVVELGAVFIGFLGTAGSTMGAASITLTVQVRKLLSGIVQQQSNLLRAIEAQQHLLKLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNKSEREIWENMTWLQWDKEISNYTHIIYELIEESQKQQEKNEQELLELDKWANLWNWFDISNWLWYIKIFIMIVGGLIGLRIVFAVLSVINRVRQGYSPLSFQTLTPNPRDPDRPGRIEGEGGEQDRGRSIRLVSGFLALAWDDLRNLCLSSYHQLRDFILIVARTVELLGHSSLKGLRLGWEGLKYLGNLLLYWGRELKTSAINLFDTIAIVVAGWTDRVIEVGQRLGRAILNIPRRIRQGLERALL |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: SER158 ASN160 THR163 ASP167 LYS168 ASN169 ARG170 LYS171 VAL172 TYR173 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
